Stockreport

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments [Seeking Alpha]

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launc [Read more]